Research & Literature

[AML treatment strategy based on cytogenetic abnormalities and somatic mutations].

Imai Y

[Rinsho ketsueki] The Japanese journal of clinical hematology 2015; (56(10)):1932-41 doi:10.11406/rinketsu.56.1932.

Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.

Benito J, Ramirez MS, Millward NZ, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(7)):1687-98 doi:10.1158/1078-0432.CCR-14-3378.

[Research Advances of IDH2 Gene Mutation in Acute Myeloid Leukemia].

Zhao YX, Shen XL

Zhongguo shi yan xue ye xue za zhi 2016; (24(2)):632-6 doi:10.7534/j.issn.1009-2137.2016.02.061.

Intensified Induction and Post-Remission Therapy for Acute Myeloid Leukaemia.

Bishop JF

Hematology (Amsterdam, Netherlands) 1996; (1(2)):91-102 doi:10.1080/10245332.1996.11746292.

Acute myeloid leukemia presenting as galactorrhea.

Nambiar KR, Nair SG, Devi RN

Proceedings (Baylor University. Medical Center) 2016; (29(4)):395 doi:10.1080/08998280.2016.11929483.

Applicability of a single 5 color cytoplasmic markers tube as primary panel for immunophenotyping of acute leukemia: A Gujarat Cancer and Research Institute experience.

Parikh BP, Patel SP, Raiya BN, et al.

Indian journal of cancer 2016; (53(3)):349-352 doi:10.4103/0019-509X.200659.

Aleukemic Myeloid Leukemia Cutis with a Kikuchi Disease-Like Inflammatory Pattern in Myelodysplastic Syndrome.

Khieu M, Beauvais A, Matz R, et al.

Southern medical journal 2017; (110(4)):308-313 doi:10.14423/SMJ.0000000000000634.

Immunohistochemistry in Acute Myeloid Leukemia.

Cruise MW

Methods in molecular biology (Clifton, N.J.) 2017; (1633()):33-49 doi:10.1007/978-1-4939-7142-8_3.

Immunophenotyping by Multiparameter Flow Cytometry.

Chen W, Luu HS

Methods in molecular biology (Clifton, N.J.) 2017; (1633()):51-73 doi:10.1007/978-1-4939-7142-8_4.

The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study.

Shysh AC, Nguyen LT, Guo M, et al.

BMC public health 2017; (18(1)):94 doi:10.1186/s12889-017-4644-6.

Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia.

Lin N, Fu W, Zhao C, et al.

Biochemical and biophysical research communications 2017; (494(1-2)):270-277 doi:10.1016/j.bbrc.2017.10.041.

Measurement of Residual Disease in Acute Myeloid Leukemia.

Vedula RS, Lindsley RC

Current hematologic malignancy reports 2017; (12(6)):574-581 doi:10.1007/s11899-017-0428-4.

Emerging molecular predictive and prognostic factors in acute myeloid leukemia.

McCurdy SR, Levis MJ

Leukemia & lymphoma 2018; (59(9)):2021-2039 doi:10.1080/10428194.2017.1393669.

Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis.

Chen X, Cherian S

Clinics in laboratory medicine 2017; (37(4)):753-769 doi:10.1016/j.cll.2017.07.003.

Leukostasis: Management to Prevent Crisis in Acute Leukemia
.

Blackburn LM, Brown S, Munyon A, Orovets M

Clinical journal of oncology nursing 2017; (21(6)):E267-E271 doi:10.1188/17.CJON.E267-E271.

Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML).

Glasser CL

Leukemia research reports 2017; (8()):19-20 doi:10.1016/j.lrr.2017.10.002.

Smear Campaign: Misattribution of Pancytopenia to a Tick-Borne Illness.

Lee J, Azzawi S, Peluso MJ, et al.

Journal of general internal medicine 2018; (33(4)):570-572 doi:10.1007/s11606-017-4241-5.

Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges.

Alfayez M, Borthakur G

Expert review of hematology 2018; (11(5)):373-389 doi:10.1080/17474086.2018.1459184.

Current status and trends in the diagnostics of AML and MDS.

Shumilov E, Flach J, Kohlmann A, et al.

Blood reviews 2018; (32(6)):508-519 doi:10.1016/j.blre.2018.04.008.

Mediastinal Myeloid Sarcoma with TP53 Mutation Preceding Acute Myeloid Leukemia with a PICALM-MLLT10 Fusion Gene.

Naesens L, Devos H, Nollet F, et al.

Acta haematologica 2018; (140(2)):97-104 doi:10.1159/000491596.

Predicting and Preventing Anthracycline-Related Cardiotoxicity.

Armenian S, Bhatia S

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018; (38()):3-12 doi:10.1200/EDBK_100015.

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

Pigneux A, Béné MC, Salmi LR, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(32)):3203-3210 doi:10.1200/JCO.2018.78.7366.

Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.

Sakaguchi M, Yamaguchi H, Najima Y, et al.

Blood advances 2018; (2(20)):2744-2754 doi:10.1182/bloodadvances.2018020305.

Surveillance for Cancers Associated with Tobacco Use - United States, 2010-2014.

Gallaway MS, Henley SJ, Steele CB, et al.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) 2018; (67(12)):1-42 doi:10.15585/mmwr.ss6712a1.

What biologic factors predict for transformation to AML?

Bejar R

Best practice & research. Clinical haematology 2018; (31(4)):341-345 doi:10.1016/j.beha.2018.10.002.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, et al.

Leukemia 2019; (33(7)):1747-1758 doi:10.1038/s41375-018-0351-2.

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.

Norsworthy KJ, Luo L, Hsu V, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(11)):3205-3209 doi:10.1158/1078-0432.CCR-18-3749.

Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.

Flores-Jiménez JA, Pimentel-Morales MA, González-Ramella O, et al.

Journal of adolescent and young adult oncology 2019; (8(4)):481-483 doi:10.1089/jayao.2018.0137.

New approaches in allogenic transplantation in AML.

Pei X, Huang X

Seminars in hematology 2019; (56(2)):147-154 doi:10.1053/j.seminhematol.2018.08.007.

What's new in consolidation therapy in AML?

Schlenk RF, Jaramillo S, Müller-Tidow C

Seminars in hematology 2019; (56(2)):96-101 doi:10.1053/j.seminhematol.2018.08.005.

JAK2-mutated acute myeloid leukemia: comparison of next-generation sequencing (NGS) and single nucleotide polymorphism array (SNPa) findings between two cases.

de Noronha TR, Mitne-Neto M, Chauffaille ML

Autopsy & case reports 2019; (9(2)):e2018084 doi:10.4322/acr.2018.084.

Side effects from acute myeloid leukemia treatment: results from a national survey.

Crossnohere NL, Richardson DR, Reinhart C, et al.

Current medical research and opinion 2019; (35(11)):1965-1970 doi:10.1080/03007995.2019.1631149.

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Tallman MS, Wang ES, Altman JK, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2019; (17(6)):721-749.

Clinical Profile and Short Term Outcome of Adult Patients with Acute Myeloid Leukemia.

Jacob S, Jacob SE, Suryanarayana BS, Dutta TK

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2019; (35(3)):431-436 doi:10.1007/s12288-018-1051-9.

Maintenance therapy in AML: The past, the present and the future.

Molica M, Breccia M, Foa R, et al.

American journal of hematology 2019; (94(11)):1254-1265 doi:10.1002/ajh.25620.

The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia

Çiftçiler R, Haznedaroğlu İC, Sayınalp N, et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology 2020; (37(2)):116-120 doi:10.4274/tjh.galenos.2019.2019.0154.

Vitamin B12 deficiency mimicking acute leukemia.

Konda M, Godbole A, Pandey S, Sasapu A

Proceedings (Baylor University. Medical Center) 2019; (32(4)):589-592 doi:10.1080/08998280.2019.1641045.

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.

Liu X, Gong Y

Biomarker research 2019; (7()):22 doi:10.1186/s40364-019-0173-z.

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy.

Richard-Carpentier G, DiNardo CD

Therapeutic advances in hematology 2019; (10()):2040620719882822 doi:10.1177/2040620719882822.

Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?

Derman BA, Larson RA

Best practice & research. Clinical haematology 2019; (32(4)):101102 doi:10.1016/j.beha.2019.101102.

How I investigate acute myeloid leukemia.

Narayanan D, Weinberg OK

International journal of laboratory hematology 2020; (42(1)):3-15 doi:10.1111/ijlh.13135.

Gingival hyperplasia as an early manifestation of acute myeloid leukemia. A retrospective review.

López-Valverde N, López-Valverde A, Gómez-de Diego R, et al.

Journal of clinical and experimental dentistry 2019; (11(12)):e1139-e1142 doi:10.4317/jced.56214.

Mapping and targeting of the leukemic microenvironment.

Witkowski MT, Kousteni S, Aifantis I

The Journal of experimental medicine 2020; (217(2)) doi:10.1084/jem.20190589.

Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia?

Ferrara F, Picardi A

Cancers 2019; (12(1)) doi:10.3390/cancers12010059.

Heart Failure in Relation to Anthracyclines and Other Chemotherapies.

Agunbiade TA, Zaghlol RY, Barac A

Methodist DeBakey cardiovascular journal 2019; (15(4)):243-249 doi:10.14797/mdcj-15-4-243.

Venetoclax in acute myeloid leukemia - current and future directions.

Lachowiez C, DiNardo CD, Konopleva M

Leukemia & lymphoma 2020; (61(6)):1313-1322 doi:10.1080/10428194.2020.1719098.

Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.

Panuzzo C, Signorino E, Calabrese C, et al.

Journal of clinical medicine 2020; (9(3)) doi:10.3390/jcm9030802.

Clinical implications of recurrent gene mutations in acute myeloid leukemia.

Yu J, Li Y, Zhang D, et al.

Experimental hematology & oncology 2020; (9()):4 doi:10.1186/s40164-020-00161-7.

Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits.

Shallis RM, Stahl M, Bewersdorf JP, et al.

Expert review of hematology 2020; (13(5)):489-499 doi:10.1080/17474086.2020.1751609.

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation.

Chew S, Mackey MC, Jabbour E

Therapeutic advances in hematology 2020; (11()):2040620720930614 doi:10.1177/2040620720930614.

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years.

Major CK, Kantarjian H, Sasaki K, et al.

Leukemia & lymphoma 2020; (61(13)):3120-3127 doi:10.1080/10428194.2020.1802450.

Acute Myocardial Infarction as Initial Manifestation of Acute Myeloid Leukemia: A Rare Manifestation of Leukostasis.

Manogna D, Sham R

Cureus 2020; (12(8)):e9551 doi:10.7759/cureus.9551.

Who Should Receive an Allogeneic Transplant in First Complete Remission?

Ribera JM, Genescà E, Ribera J

Clinical lymphoma, myeloma & leukemia 2020; (20 Suppl 1()):S48-S51 doi:10.1016/S2152-2650(20)30459-6.

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Ballesta-López O, Solana-Altabella A, Megías-Vericat JE, et al.

Future oncology (London, England) 2021; (17(2)):215-227 doi:10.2217/fon-2020-0700.

Acute Coronary Syndrome in Acute Myeloid Leukemia with Maturation Accompanying Megakaryocytic Differentiation.

Odani K, Abe J, Tsuyuki Y, et al.

Case reports in pathology 2020; (2020()):8886298 doi:10.1155/2020/8886298.

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?

Bewersdorf JP, Zeidan AM

Cells 2020; (9(10)) doi:10.3390/cells9102310.

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.

Pollyea DA, Pratz K, Letai A, et al.

American journal of hematology 2021; (96(2)):208-217 doi:10.1002/ajh.26039.

Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.

Gaut D, Mead M

Leukemia & lymphoma 2021; (62(1)):8-31 doi:10.1080/10428194.2020.1827251.

Genetic heterogeneity and clonal evolution in acute myeloid leukemia.

Romer-Seibert JS, Meyer SE

Current opinion in hematology 2021; (28(1)):64-70 doi:10.1097/MOH.0000000000000626.

Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.

Chen X, Othus M, Wood BL, et al.

Leukemia & lymphoma 2021; (62(5)):1226-1233 doi:10.1080/10428194.2020.1861267.

Understanding of the crosstalk between normal residual hematopoietic stem cells and the leukemic niche in acute myeloid leukemia.

Batsivari A, Grey W, Bonnet D

Experimental hematology 2021; (95()):23-30 doi:10.1016/j.exphem.2021.01.004.

Acute myeloid leukemia: current progress and future directions.

Kantarjian H, Kadia T, DiNardo C, et al.

Blood cancer journal 2021; (11(2)):41 doi:10.1038/s41408-021-00425-3.

Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.

Isobe M, Konuma T, Masuko M, et al.

Annals of hematology 2021; (100(7)):1849-1861 doi:10.1007/s00277-021-04464-5.

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia.

Loke J, Vyas H, Craddock C

Frontiers in oncology 2021; (11()):666091 doi:10.3389/fonc.2021.666091.

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.

Tsai CH, Tang JL, Tien FM, et al.

Blood advances 2021; (5(10)):2456-2466 doi:10.1182/bloodadvances.2020003738.

Acute Myeloid Leukemia Complicated by Hyperleukocytosis and Leukostasis in the Emergency Department.

Ngo RT, Webb McAdams AL, Furiato A

Cureus 2021; (13(6)):e15392 doi:10.7759/cureus.15392.

Treatment for Relapsed/Refractory Acute Myeloid Leukemia.

Thol F, Heuser M

HemaSphere 2021; (5(6)):e572 doi:10.1097/HS9.0000000000000572.

Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?

Jaramillo S, Schlenk RF

Current oncology reports 2021; (23(9)):109 doi:10.1007/s11912-021-01092-0.

Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia.

Chen X, Cherian S

Clinics in laboratory medicine 2021; (41(3)):467-483 doi:10.1016/j.cll.2021.03.017.

SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.

Inguva A, Pollyea DA

Clinical lymphoma, myeloma & leukemia 2021; (21(12)):805-811 doi:10.1016/j.clml.2021.07.012.

Oral manifestations of systemic leukemia-first sign of presentation.

Bhambal AM, Shrivastava H, Naik SP, et al.

Journal of Indian Society of Periodontology 2021; (25(4)):347-349 doi:10.4103/jisp.jisp_551_20.

Alternatives to intensive treatment in patients with AML.

Himmelstein G, Mascarenhas J, Marcellino BK

Clinical advances in hematology & oncology : H&O 2021; (19(8)):526-535.

Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.

Harries I, Berlot B, Ffrench-Constant N, et al.

International journal of cardiology 2021; (343()):180-186 doi:10.1016/j.ijcard.2021.08.037.

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.

Issa GC, Zarka J, Sasaki K, et al.

Blood cancer journal 2021; (11(9)):162 doi:10.1038/s41408-021-00557-6.

SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML.

Saxena K, DiNardo C, Daver N, Konopleva M

Clinical lymphoma, myeloma & leukemia 2022; (22(3)):133-139 doi:10.1016/j.clml.2021.08.015.

ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment.

Chiu M, Taurino G, Dander E, et al.

Blood advances 2021; (5(23)):5164-5178 doi:10.1182/bloodadvances.2020004041.

Acute Myeloid Leukemia with Myelodysplasia-Related Changes Presenting as Vitamin B12 Deficiency: A Cautionary Tale.

Gereg C, Conant JL, Jasra S, et al.

Journal of the Association of Genetic Technologists 2021; (47(4)):218-223.

Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor.

Si H, Wang J, He R, et al.

Frontiers in oncology 2021; (11()):807200 doi:10.3389/fonc.2021.807200.

Consensus in acute myeloid leukemia in Mexico.

Arana-Luna LL, Alvarado-Ibarra M, Silva-Michel LG, et al.

Gaceta medica de Mexico 2022; (158(M3)):M1-M48 doi:10.24875/GMM.M21000598.

The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients.

Raza H, Fatima M, Noor T, et al.

Cureus 2022; (14(2)):e22309 doi:10.7759/cureus.22309.

Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy.

Hadisantoso DW, Ranuhardy D, Rajabto W, et al.

F1000Research 2022; (11()):495 doi:10.12688/f1000research.110320.2.

Investigation of Biomarkers Associated with Low Platelet Counts in Normal Karyotype Acute Myeloid Leukemia.

Park CH, Yun JW

International journal of molecular sciences 2022; (23(14)) doi:10.3390/ijms23147772.

Real-world analysis of tumor lysis syndrome in patients started on venetoclax combination for acute myeloid leukemia.

Abernathy KM, Perciavalle MA, Gatwood KS, et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023; (29(6)):1326-1333 doi:10.1177/10781552221118635.

Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults.

Granroth G, Khera N, Arana Yi C

Current hematologic malignancy reports 2022; (17(6)):243-253 doi:10.1007/s11899-022-00680-6.

Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia.

Amonoo HL, Daskalakis E, Deary EC, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(10)):1116-1123.

Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.

Huggar D, Knoth RL, Copher R, et al.

Future oncology (London, England) 2022; (18(32)):3609-3621 doi:10.2217/fon-2022-0706.

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy.

Lockwood BJ, El-Jawahri A, Walker AR, et al.

Journal of adolescent and young adult oncology 2023; (12(4)):592-598 doi:10.1089/jayao.2022.0082.

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.

Lachowiez CA, Long N, Saultz J, et al.

Blood advances 2023; (7(9)):1899-1909 doi:10.1182/bloodadvances.2022009010.

Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review.

Hao Q, Foroutan F, Han MA, et al.

PloS one 2022; (17(12)):e0278578 doi:10.1371/journal.pone.0278578.

Acute Myeloid Leukaemia Presenting as B12 Vitamin Deficiency When Multiple Horses Become a Zebra.

Ferrão D, Gonçalves F, Almeida J

European journal of case reports in internal medicine 2022; (9(11)):003635 doi:10.12890/2022_003635.

Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.

Baumrin E, Loren AW, Falk SJ, et al.

Journal of the American Academy of Dermatology 2024; (90(1)):19-36 doi:10.1016/j.jaad.2022.12.023.

Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.

Baumrin E, Loren AW, Falk SJ, et al.

Journal of the American Academy of Dermatology 2024; (90(1)):1-16 doi:10.1016/j.jaad.2022.12.024.

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.

Kuron D, Pohlmann A, Angenendt L, et al.

Annals of hematology 2023; (102(4)):755-760 doi:10.1007/s00277-023-05111-x.

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Badar T, Atallah E, Shallis R, et al.

Leukemia 2023; (37(4)):799-806 doi:10.1038/s41375-023-01847-7.

Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka.

Sandamali JAN, Hewawasam RP, Fernando MACSS, Jayatilaka KAPW

BMC cancer 2023; (23(1)):210 doi:10.1186/s12885-023-10673-0.

[Novel Strategies to Treat Acute Myeloid Leukemia].

Gediga MHE, Middeke JM, Ruhnke L

Deutsche medizinische Wochenschrift (1946) 2023; (148(8)):451-458 doi:10.1055/a-1873-4753.

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.

Dillon LW, Higgins J, Nasif H, et al.

medRxiv : the preprint server for health sciences 2023; doi:10.1101/2023.03.26.23287367.

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.

Sargas C, Ayala R, Larráyoz MJ, et al.

Blood cancer journal 2023; (13(1)):77 doi:10.1038/s41408-023-00835-5.

Late-onset doxorubicin-induced congestive heart failure in an elderly cancer survivor: A case report.

Suto H, Suto M, Inui Y, Okamura A

Frontiers in cardiovascular medicine 2023; (10()):1124276 doi:10.3389/fcvm.2023.1124276.

Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder.

Yiğit Kaya S, Askin AE, Bektas S, et al.

Leukemia research reports 2023; (19()):100369 doi:10.1016/j.lrr.2023.100369.

Novel Tools for Diagnosis and Monitoring of AML.

Guijarro F, Garrote M, Villamor N, et al.

Current oncology (Toronto, Ont.) 2023; (30(6)):5201-5213 doi:10.3390/curroncol30060395.

Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors.

Boscaro E, Urbino I, Catania FM, et al.

Cancers 2023; (15(13)) doi:10.3390/cancers15133512.

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.

Dillon LW, Higgins J, Nasif H, et al.

Haematologica 2024; (109(2)):401-410 doi:10.3324/haematol.2023.283520.

Paraplegia as a Rare Clinical Presentation of Relapsed Acute Myeloid Leukemia.

Osman H, Gism Elseed I, Hussein SB, et al.

Cureus 2023; (15(7)):e41421 doi:10.7759/cureus.41421.

FLT3-ITD Mutation and Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Case Study.

Saeed S, Halappa Nagaraj R, Grezenko H, et al.

Cureus 2023; (15(7)):e42504 doi:10.7759/cureus.42504.

Location, location, location: A mini-review of CEBPA variants in patients with acute myeloid leukemia.

Faisal MS, Sung PJ

Leukemia research reports 2023; (20()):100386 doi:10.1016/j.lrr.2023.100386.

AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.

Zhao D, Zhou Q, Zarif M, et al.

Leukemia research 2023; (134()):107376 doi:10.1016/j.leukres.2023.107376.

Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia.

Park S, Kim TY, Cho BS, et al.

Haematologica 2024; (109(4)):1095-1106 doi:10.3324/haematol.2023.283606.

A Patient Presenting for Dental Extraction After Completion of Chemotherapy.

Hong WW, Kim IH, Hong BM, et al.

Dental clinics of North America 2023; (67(4)):667-670 doi:10.1016/j.cden.2023.05.020.

Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes.

Kwon A, Weinberg OK

Clinics in laboratory medicine 2023; (43(4)):657-667 doi:10.1016/j.cll.2023.07.001.

FLT3 Mutations in Acute Myeloid Leukemia: Unraveling the Molecular Mechanisms and Implications for Targeted Therapies.

Jalte M, Abbassi M, El Mouhi H, et al.

Cureus 2023; (15(9)):e45765 doi:10.7759/cureus.45765.

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.

Falini B, Dillon R

Blood cancer discovery 2024; (5(1)):8-20 doi:10.1158/2643-3230.BCD-23-0144.

Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment.

Robak E, Braun M, Robak T

Cancers 2023; (15(22)) doi:10.3390/cancers15225393.

Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy.

Bolkun L, Pienkowski T, Sieminska J, et al.

Scientific reports 2023; (13(1)):21809 doi:10.1038/s41598-023-48970-0.

Myeloid Sarcoma: Case Series with Unusual Locations.

Abedi A, Namdari N, Monabati A, et al.

International journal of hematology-oncology and stem cell research 2023; (17(4)):296-303 doi:10.18502/ijhoscr.v17i4.13922.

Cognitive-behavioral stress management relieves anxiety, depression, and post-traumatic stress disorder in parents of pediatric acute myeloid leukemia patients: a randomized, controlled study.

Wang L, Duan H, Zuo H, et al.

Hematology (Amsterdam, Netherlands) 2024; (29(1)):2293498 doi:10.1080/16078454.2023.2293498.

Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.

Chen E, Jiao C, Yu J, et al.

Cancer medicine 2023; (12(24)):21615-21626 doi:10.1002/cam4.6696.

Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.

Baron F, Efficace F, Cannella L, et al.

American journal of hematology 2024; (99(3)):486-489 doi:10.1002/ajh.27196.

Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.

Chen X, Yuan L, Zhang Y, et al.

American journal of hematology 2024; (99(5)):824-835 doi:10.1002/ajh.27249.

What is new in acute myeloid leukemia classification?

Park HS

Blood research 2024; (59(1)):15 doi:10.1007/s44313-024-00016-8.

Acute calcareous corneal degeneration in a patient with chronic graft-versus-host disease.

Ruiz MGS, Pérez LA, Picazo CC, et al.

Romanian journal of ophthalmology 2024; (68(1)):53-56 doi:10.22336/rjo.2024.10.

CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.

Tien FM, Hou HA

International journal of hematology 2024; (120(5)):541-547 doi:10.1007/s12185-024-03773-5.

Sickle Cell Anomaly Meets Leukemic Challenge: A Case Report.

Mandviya SH, Hingway S, Wanjari M, et al.

Cureus 2024; (16(3)):e57089 doi:10.7759/cureus.57089.

Late Adverse Effects after Treatment for Childhood Acute Leukemia.

Roganovic J, Haupt R, Bárdi E, et al.

Acta medica academica 2024; (53(1)):59-80 doi:10.5644/ama2006-124.438.

Mapping the Grounds for Mortalities in Acute Myeloid Leukemia Through Registry Analyses: A Retrospective Cohort Study of Children, Adolescents, and Young Adults Patients.

Elgenidy A, Al-Kurdi MA, Ibrahim HAA, et al.

Journal of clinical medicine research 2024; (16(6)):310-318 doi:10.14740/jocmr5205.

An Extensive Analysis and Comparison of Bone Marrow Aspiration and Bone Marrow Trephine Biopsy at a Tertiary Care Hospital in Jharkhand for Various Hematological and Non-hematological Illnesses.

Jawed MA, Paswan MK, Mahto SK, et al.

Cureus 2024; (16(6)):e62661 doi:10.7759/cureus.62661.

Acute myeloid leukemia following remission of AIDS-associated extra-nodal NK/T-cell lymphoma.

Fan S, Zhou Q, Zhou Z, et al.

Heliyon 2024; (10(13)):e33622 doi:10.1016/j.heliyon.2024.e33622.

Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.

Al Hamed R, Labopin M, Wu D, et al.

Bone marrow transplantation 2024; (59(10)):1458-1465 doi:10.1038/s41409-024-02373-5.

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

Hoff FW, Blum WG, Huang Y, et al.

Blood advances 2024; (8(20)):5297-5305 doi:10.1182/bloodadvances.2024013685.

Contemporary Management of Acute Myeloid Leukemia: A Review.

Venugopal S, Sekeres MA

JAMA oncology 2024; (10(10)):1417-1425 doi:10.1001/jamaoncol.2024.2662.

Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions.

Salman H

Cancers 2024; (16(16)) doi:10.3390/cancers16162915.

Current status and research directions in acute myeloid leukemia.

Kantarjian H, Borthakur G, Daver N, et al.

Blood cancer journal 2024; (14(1)):163 doi:10.1038/s41408-024-01143-2.

Oral Chronic Graft-versus-Host Disease and Oral Health after Allogeneic Hematopoietic Cell Transplantation - What the Care Team Needs to Know.

Laheij AMGA, Fregnani ER, de Macedo LD, Treister NS

Transplantation and cellular therapy 2024; (30(9S)):S548-S558 doi:10.1016/j.jtct.2024.07.006.

Oral Chronic Graft-Versus-Host Disease: Pathogenesis, Diagnosis, Current Treatment, and Emerging Therapies.

Nguyen JT, Jessri M, Costa-da-Silva AC, et al.

International journal of molecular sciences 2024; (25(19)) doi:10.3390/ijms251910411.

Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.

Battiwalla M, Chao JH, Cox T, et al.

Clinical hematology international 2024; (6(4)):43-52 doi:10.46989/001c.124273.

Prognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience.

Bülbül H, Kaya ÖÖ, Karadağ FK, et al.

Medicine 2024; (103(41)):e39909 doi:10.1097/MD.0000000000039909.

Acute myeloid leukemia management and research in 2025.

Kantarjian HM, DiNardo CD, Kadia TM, et al.

CA: a cancer journal for clinicians 2025; (75(1)):46-67 doi:10.3322/caac.21873.

Incorporation of a Comorbidity Index in Treatment Decisions for Elderly AML Patients Can Lead to Better Disease Management-A Single-Center Experience.

Negotei C, Mitu I, Angelescu S, et al.

Hematology reports 2024; (16(4)):781-794 doi:10.3390/hematolrep16040074.

Second primary non-myeloid malignancies following intensive treatment for adult acute myeloid leukaemia: a Danish population-based cohort study.

Nielsen NN, Jensen JF, Baech J, et al.

The Lancet regional health. Europe 2025; (50()):101204 doi:10.1016/j.lanepe.2024.101204.

Combination of 2-Chlorodeoxyadenosine, Cytarabine, and Granulocyte Colony-Stimulating Factor and Venetoclax in a Case of Acute Myelogenous Leukemia.

Jackert EP, Woan K, Chaudhary P, et al.

Journal of medical cases 2025; (16(3)):102-106 doi:10.14740/jmc5087.

The demographic characteristics and prognosis of acute myeloid leukemia with t(3;3)/inv(3) in the united states: a SEER-based study.

Ouyang X, Wu X, Hu S, et al.

Scientific reports 2025; (15(1)):13477 doi:10.1038/s41598-025-95783-4.

Coexistence of Acute Myeloid Leukemia and B-cell Non-Hodgkin Lymphoma Diagnosed on a Bone Marrow Trephine Biopsy.

Ahmad N, Asif H, Burhan M, et al.

Cureus 2025; (17(3)):e81107 doi:10.7759/cureus.81107.

Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML.

Inoue Y, Cioccio J, Mineishi S, Minagawa K

Cells 2025; (14(8)) doi:10.3390/cells14080572.

Effect of cyclophospamide, doxorubicin, vincristine and prednisone/prednisolone (CHOP) chemotherapy regimens on left ventricular systolic function and cardiac structural abnormalities in non-Hodgkin lymphoma patients.

Septianda I, Alsagaff MY, Pikir BS, et al.

Journal of the Egyptian National Cancer Institute 2025; (37(1)):29 doi:10.1186/s43046-025-00288-w.

Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort.

Wangulu C, Zhao D, Zhou Q, et al.

Cancers 2025; (17(9)) doi:10.3390/cancers17091405.

Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Lachowiez CA, Asimomitis G, Bernard E, et al.

Blood cancer discovery 2025; (6(5)):425-436 doi:10.1158/2643-3230.BCD-25-0047.

Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast].

Zeidan AM, Wang E

Blood and lymphatic cancer : targets and therapy 2025; (15()):69-75 doi:10.2147/BLCTT.S548242.

Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group.

Wen Q, Jiang C, Liu X, et al.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2025; (37(3)):417-431 doi:10.21147/j.issn.1000-9604.2025.03.10.

Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy.

Song F, Lin S, Xu T, et al.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2025; (83()):101286 doi:10.1016/j.drup.2025.101286.

[Future treatment strategies for acute myeloid leukemia].

Najima Y

[Rinsho ketsueki] The Japanese journal of clinical hematology 2025; (66(7)):590-596 doi:10.11406/rinketsu.66.590.

Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.

Geels J, van Rhenen A, Gradowska P, et al.

Leukemia 2026; (40(1)):120-129 doi:10.1038/s41375-025-02753-w.

Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project.

Pinar IE, Celik S, Polat MG, et al.

BMC cancer 2025; (25(1)):1546 doi:10.1186/s12885-025-14987-z.

Tailoring intensive and less-intensive treatment in acute myeloid leukemia.

Seeling C, Ganser A, Döhner H, Kühn MWM

Seminars in hematology 2025; (62(3)):196-208 doi:10.1053/j.seminhematol.2025.09.001.

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Bill M, Eckardt JN, Döhner K, et al.

Leukemia 2026; (40(1)):63-71 doi:10.1038/s41375-025-02781-6.

Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.

Hunter CJ, Cheng W, Bewersdorf JP, et al.

Leukemia & lymphoma 2026; (67(1)):164-175 doi:10.1080/10428194.2025.2578420.

Allogeneic transplantation in adverse-risk acute myeloid leukemia: Challenges, strategies, and future directions.

Huang J, Wu X, Wang G, et al.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2025; (37(5)):718-736 doi:10.21147/j.issn.1000-9604.2025.05.05.

Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance.

Huang J, Xia Y, Xiang M, et al.

Transplantation and cellular therapy 2025; doi:10.1016/j.jtct.2025.12.951.

T Lymphocyte Reconstitution in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation: A Single Center Experience (2016-2023).

Nguyen KB, Nguyen NTH, Vo BTT, Nguyen TH

Transplantation proceedings 2026; (58(1)):202-206 doi:10.1016/j.transproceed.2025.11.014.

Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

Hernández-Sánchez A, Villaverde Ramiro Á, Sträng E, et al.

Leukemia 2026; (40(2)):418-428 doi:10.1038/s41375-025-02851-9.

Aberrant expression of CD markers in patients with acute leukemia.

Habeeb AR, Al-Tameemi H, Abdullah DAA, et al.

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 2025; (53(6)):734-741 doi:10.36740/Merkur202506104.

Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.

Chang YS, Lee YW, Liu CY, et al.

Haematologica 2026; doi:10.3324/haematol.2025.288081.

[Venetoclax plus azacitidine as successful bridging therapy to second transplantation for post-transplant extramedullary relapse of acute myeloid leukemia].

Endo T, Takahashi H, Namiki T, et al.

[Rinsho ketsueki] The Japanese journal of clinical hematology 2026; (67(2)):124-128 doi:10.11406/rinketsu.67.124.